Lenalidomide Ranbaxy

Lenalidomide, the active ingredient in Lenalidomide Ranbaxy, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients who have relapsed or refractory disease and require systemic therapy.

GNH USA supplies Lenalidomide Ranbaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies. - Multiple myeloma (newly diagnosed): enhances response rates when combined with dexamethasone. - Multiple myeloma (relapsed/refractory): provides disease control after prior therapies. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Diarrhea: loose stools that may require fluid replacement. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound drop in neutrophils requiring medical intervention. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thrombotic risk: evaluate history of clotting disorders and consider prophylaxis. - Contraindicated in pregnancy: avoid use in pregnant women and ensure effective contraception. - Adjust for renal impairment: dose may need modification in reduced kidney function. - Counsel on contraception: both male and female patients must use reliable birth control. - Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may lower lenalidomide exposure. - Live vaccines: increased risk of infection due to immunomodulation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise drug levels. - Anticoagulants (e.g., warfarin): heightened risk of thrombosis. - NSAIDs: may exacerbate gastrointestinal irritation.